Nonalcoholic Fatty Liver Disease

Treatment with Egrifta demonstrated a greater reduction in hepatic fat fraction compared with placebo among patients with nonalcoholic fatty liver disease and HIV, according to study results.

Changes in liver fat can predict changes in steatosis but not other liver histological parameters like improvements in nonalcoholic fatty liver disease activity score or resolution of nonalcoholic steatohepatitis without worsening of fibrosis, according to data published in Journal of Hepatology.

Prospective study data presented at the European Academy of Dermatology and Venereology Congress demonstrated that psoriasis severity is associated with more severe hepatic damage among patients with both psoriasis and nonalcoholic fatty liver disease. Specifically, an increase in PASI score by one was associated with an increase in elastography of, on average, 0.26 kPa.

Researchers found that while consumption of red and processed meat, poultry, and cholesterol correlated with nonalcoholic fatty liver disease, dietary fiber intake may reduce the risk for fatty liver and related advanced liver disease, according to data from a multiethnic cohort study.

Investigators have completed trial enrollment for two novel compositions of endogenous metabolic modulators under evaluation as interventions to address dysregulated metabolism in patients with nonalcoholic fatty liver disease, according to a press release from Axcella.

NGM Bio announced positive interim results from ongoing study of aldafermin, an engineered version of human fibroblast growth factor 19 that demonstrated reductions in liver fat among patients with nonalcoholic steatohepatitis, according to a press release.

Results from the EVIDENCES IV trial showed that saroglitazar magnesium achieved its primary endpoint of reduced alanine aminotransferase in patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release from Zydus Calida.

SAN ANTONIO — Healio will host its second Disruptive Innovators reception during the American College of Gastroenterology’s Annual Scientific Meeting (ACG 2019) on October 27, 2019, at the Grand Hyatt San Antonio.

Dual-photon microscopy automated quantification of fibrosis-related parameters provided accurate assessments of fibrosis in patients with nonalcoholic fatty liver disease, according to data published in Gut.

Enanta Pharmaceuticals announced positive results in alanine aminotransferase and liver fat content reduction from its current trial of EDP-305, a small molecule farnesoid X receptor under investigation for the treatment of nonalcoholic steatohepatitis, according to a press release.